Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial.
Landewé RB, Houbiers JG, Van den Bosch F, in't Hout J, Verschueren PC, Meijerink JH, van den Hoogen FH, Masek BA, Bruyn GA, Wouters JM, Voskuyl AE, van Laar JM, Bijlsma JJ, van der Heijde DM, Breedveld FC, van de Putte LB, Miltenburg AM, de Keyser F.
Landewé RB, et al. Among authors: houbiers jg.
Ann Rheum Dis. 2010 Sep;69(9):1655-9. doi: 10.1136/ard.2009.117234. Epub 2009 Sep 23.
Ann Rheum Dis. 2010.
PMID: 19778914
Clinical Trial.